- Home
- PRT vs ANTX Comparison
PRT vs ANTX Comparison
Compare PRT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- ANTX
- Stock Information
- Founded
- PRT 2017
- ANTX 2017
- Country
- PRT United States
- ANTX United States
- Employees
- PRT N/A
- ANTX N/A
- Industry
- PRT Oil & Gas Production
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- ANTX Health Care
- Exchange
- PRT Nasdaq
- ANTX Nasdaq
- Market Cap
- PRT 45.4M
- ANTX 40.0M
- IPO Year
- PRT N/A
- ANTX 2022
- Fundamental
- Price
- PRT $3.28
- ANTX $1.32
- Analyst Decision
- PRT
- ANTX Hold
- Analyst Count
- PRT 0
- ANTX 5
- Target Price
- PRT N/A
- ANTX $3.50
- AVG Volume (30 Days)
- PRT 49.6K
- ANTX 833.6K
- Earning Date
- PRT 11-13-2024
- ANTX 11-13-2024
- Dividend Yield
- PRT 12.13%
- ANTX N/A
- EPS Growth
- PRT N/A
- ANTX N/A
- EPS
- PRT 0.42
- ANTX N/A
- Revenue
- PRT $6,059,380.00
- ANTX N/A
- Revenue This Year
- PRT N/A
- ANTX N/A
- Revenue Next Year
- PRT N/A
- ANTX N/A
- P/E Ratio
- PRT $8.17
- ANTX N/A
- Revenue Growth
- PRT N/A
- ANTX N/A
- 52 Week Low
- PRT $3.27
- ANTX $0.87
- 52 Week High
- PRT $5.03
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- PRT 22.25
- ANTX 50.02
- Support Level
- PRT $3.61
- ANTX $1.32
- Resistance Level
- PRT $4.05
- ANTX $1.59
- Average True Range (ATR)
- PRT 0.16
- ANTX 0.09
- MACD
- PRT -0.05
- ANTX -0.03
- Stochastic Oscillator
- PRT 2.59
- ANTX 7.89
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.